Stellate Ganglion Destruction With Alcohol Versus Thermal Ablation for Chronic Post Mastectomy Pain

Sponsor
National Cancer Institute, Egypt (Other)
Overall Status
Recruiting
CT.gov ID
NCT05771103
Collaborator
(none)
70
1
2
4.9
14.3

Study Details

Study Description

Brief Summary

  • Group A: SGB with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.

  • Group B: Thermal RF; thermal RF neurolysis will be applied with a time of 60 seconds at 80º C, and then will be repeated twice after needle-tip rotation. Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance

Condition or Disease Intervention/Treatment Phase
  • Device: thermal Radiofrequency neurolysis of Stellate ganglion
N/A

Detailed Description

Breast cancer is the most common cause of cancer death for women . Postmastectomy pain syndrome (PMPS) is a frequent complication of breast surgery, and is considered a chronic neuropathic pain in the side of surgery which persists more than 3 months.

Complex regional pain syndrome (CRPS) is a clinical diagnosis with a highly variable presentation and prognosis. CRPS type I, previously known as reflex sympathetic dystrophy (RSD), is not associated with direct nerve injury. CRPS type II, or causalgia, is associated with direct injury of a specific nerve often from surgical intervention or trauma.

The stellate ganglion (SG), also known as the cervico-thoracic ganglion, is part of the sympathetic nervous system.

After assessment of eligibility criteria a predetermined randomization list and will be generated using random blocks.

  • Group A: SGB with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.

  • Group B: Thermal RF; thermal RF neurolysis will be applied with a time of 60 seconds at 80º C, and then will be repeated twice after needle-tip rotation. Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance

  • Group A ,The procedure will be started by placing the needle tip аntеrоlаteral to the lоngusсоlli muscle, dееp to the prеvеrtebrаlfаsсia in оrdеr tо аvоid spread along the carotid sheath, but superficial to the fascia investing the longus colli muscle (to prevent injecting into the muscle). Identifying the correct fascial plane achieved with portable ultrasound guidance thus facilitating the caudal spread of the injectate to reach the stellate ganglion at the C7-T1 level. This allowed for a more effective and stable sympathetic block with the use of a small injected volume. As an injection, we firstly used 2%-5.0 ml of lidocaine. The procedure will be continued by the injection of ethanol 50%, in quantity 0.5 ml for a lasting effect.

  • Group B, thermal RF neurolysis will be applied with a time of 60 seconds at 80º C, and then will be repeated twice after needle-tip rotation. Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Stellate Ganglion Destruction With Alcohol Versus Thermal Ablation for Chronic Post Mastectomy Pain
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
May 30, 2023
Anticipated Study Completion Date :
May 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Stellate ganglion block with alcohol injection

Stellate ganglion block with alcohol injection by ultrasound guidance and C7 level confirmation by fluoroscopy.

Device: thermal Radiofrequency neurolysis of Stellate ganglion
Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
Other Names:
  • Stellate ganglion block with alcohol injection
  • Active Comparator: thermal RF neurolysis of Stellate ganglion

    Stellate ganglion RF therapy will be done under fluoroscopy, integrated by ultrasound guidance

    Device: thermal Radiofrequency neurolysis of Stellate ganglion
    Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
    Other Names:
  • Stellate ganglion block with alcohol injection
  • Outcome Measures

    Primary Outcome Measures

    1. Changes in VAS [12 WEEKS]

      assessment of pain relief pre and post neuro destruction of stellate ganglion 1, 4, 8 and 12 weeks both at rest and during movement . A 100 mm horizontal line version was used with 2 ends (left-end means no pain and right-end means the worst pain). Changes in VAS for assessment of pain relief pre and post neuro destruction of stellate ganglion 1, 4, 8 and 12 weeks. A 100 mm horizontal line version was used with 2 ends (left-end means no pain and right-end means the worst pain). Changes in VAS for assessment of pain relief pre and post neuro destruction of stellate ganglion 1, 4, 8 and 12 weeks. A 100 mm horizontal line version was used with 2 ends (left-end means no pain and right-end means the worst pain).

    Secondary Outcome Measures

    1. patient satisfaction by patient satisfaction score and the analgesic concomitant medications consumption will be assessed before and 1,4,8 and 12 weeks after block [12 weeks]

      satisfaction score where 0 very satisfied 10 dissatisfied

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 65 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Female patient 20-65yrs underwent surgery for breast cancer

    • Pain duration of more than 6 months and less than 2 years

    • Pain is moderate to severe pain (visual analog scale [VAS] ≥ 40 mm),

    • Pain described as a refractory one that is defined as pain for which classic biomedical therapy has proven ineffective

    • Pain is of positive neuropathic character as detected by the grading system for neuropathic pain (GSNP), with a score of 3 or 4

    Exclusion Criteria:
    • Refusal of the patient

    • Recent myocardial infarction

    • Anti-coagulated patients or coagulopathy (evaluate risk/benefit ratio)

    • Glaucoma

    • Pre-existing counter lateral nerve palsy

    • Severe emphysema

    • Cardiac conduction block

    • Local and systemic sepsis

    • Local anatomical distortion (which may render the block technically difficult or hazardous.

    • Psychiatric illness.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NCIEgypt IRB office Cairo Egypt 11796

    Sponsors and Collaborators

    • National Cancer Institute, Egypt

    Investigators

    • Principal Investigator: suzan adlan, lecturer, National Cancer Institute, Egypt

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    National Cancer Institute, Egypt
    ClinicalTrials.gov Identifier:
    NCT05771103
    Other Study ID Numbers:
    • AP2212-501-027
    First Posted:
    Mar 16, 2023
    Last Update Posted:
    Mar 16, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 16, 2023